Skip to main content
Erschienen in:

06.11.2019 | Original Investigation

Predictors and prognostic impact of secondary mitral regurgitation in myocardial infarction with preserved ejection fraction

verfasst von: Maki Nogi, Hiroyuki Okura, Toru Kataoka, Kiyoshi Yoshida

Erschienen in: Journal of Echocardiography | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Secondary or functional mitral regurgitation (FMR) has been reported associated with poor prognosis in patients with ischemic or non-ischemic cardiomyopathy. Prognostic impact of the FMR in myocardial infarction with preserved ejection fraction (MIpEF) is unknown. The aim of this study was to investigate predictors and prognostic impact of FMR in MIpEF.

Methods

A total of 556 patients with MIpEF were selected from the Bell Land General Hospital MI (BELAMI) registry (n = 953). Patients were grouped according to the presence or absence of severe FMR. Clinical endpoint was all-cause death.

Results

Severe FMR was present in 26 patients (4.7%) (FMR group) and absent in 530 patients (control). FMR group was older (77.5 ± 7.2 vs. 67.3 ± 11.3 years, P < 0.01) and had more female gender (54% vs. 28%, P < 0.01). By echocardiography, FMR group had larger left atrial diameter and left ventricular end-systolic volume. E and E/e′ were significantly higher and deceleration time of E was significantly shorter in FMR group. By Kaplan–Meier analysis, survival was significantly lower in FMR group than in control (log-rank, P = 0.004).

Conclusion

Severe FMR is rare in MI patients with preserved EF but is associated with poor long-term prognosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Okura H, Takada Y, Kubo T, et al. Functional mitral regurgitation predicts prognosis independent of left ventricular systolic and diastolic indices in patients with ischemic heart disease. J Am Soc Echocardiogr. 2008;21(4):355–60.CrossRef Okura H, Takada Y, Kubo T, et al. Functional mitral regurgitation predicts prognosis independent of left ventricular systolic and diastolic indices in patients with ischemic heart disease. J Am Soc Echocardiogr. 2008;21(4):355–60.CrossRef
2.
Zurück zum Zitat Okura H, Kataoka T, Yoshida K. Renin–angiotensin system inhibitors in patients with myocardial infarction and secondary mitral regurgitation. Heart. 2016;102(9):694–700.CrossRef Okura H, Kataoka T, Yoshida K. Renin–angiotensin system inhibitors in patients with myocardial infarction and secondary mitral regurgitation. Heart. 2016;102(9):694–700.CrossRef
3.
Zurück zum Zitat Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63(22):e57–185.CrossRef Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63(22):e57–185.CrossRef
4.
Zurück zum Zitat Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–91.CrossRef Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–91.CrossRef
5.
Zurück zum Zitat Marechaux S, Pibarot P, Ennezat PV. Insights into functional mitral regurgitation despite preserved LVEF. Arch Cardiovasc Dis. 2011;104(2):131–3.CrossRef Marechaux S, Pibarot P, Ennezat PV. Insights into functional mitral regurgitation despite preserved LVEF. Arch Cardiovasc Dis. 2011;104(2):131–3.CrossRef
6.
Zurück zum Zitat Ennezat PV, Marechaux S, Pibarot P, et al. Secondary mitral regurgitation in heart failure with reduced or preserved left ventricular ejection fraction. Cardiology. 2013;125(2):110–7.CrossRef Ennezat PV, Marechaux S, Pibarot P, et al. Secondary mitral regurgitation in heart failure with reduced or preserved left ventricular ejection fraction. Cardiology. 2013;125(2):110–7.CrossRef
7.
Zurück zum Zitat Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiography. J Am Soc Echocardiogr. 2003;16(7):777–802.CrossRef Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiography. J Am Soc Echocardiogr. 2003;16(7):777–802.CrossRef
8.
Zurück zum Zitat Otsuji Y, Handschumacher MD, Schwammenthal E, et al. Insights from three-dimensional echocardiography into the mechanism of functional mitral regurgitation: direct in vivo demonstration of altered leaflet tethering geometry. Circulation. 1997;96(6):1999–2008.CrossRef Otsuji Y, Handschumacher MD, Schwammenthal E, et al. Insights from three-dimensional echocardiography into the mechanism of functional mitral regurgitation: direct in vivo demonstration of altered leaflet tethering geometry. Circulation. 1997;96(6):1999–2008.CrossRef
9.
Zurück zum Zitat Otsuji Y, Handschumacher MD, Liel-Cohen N, et al. Mechanism of ischemic mitral regurgitation with segmental left ventricular dysfunction: three-dimensional echocardiographic studies in models of acute and chronic progressive regurgitation. J Am Coll Cardiol. 2001;37(2):641–8.CrossRef Otsuji Y, Handschumacher MD, Liel-Cohen N, et al. Mechanism of ischemic mitral regurgitation with segmental left ventricular dysfunction: three-dimensional echocardiographic studies in models of acute and chronic progressive regurgitation. J Am Coll Cardiol. 2001;37(2):641–8.CrossRef
10.
Zurück zum Zitat Saito K, Okura H, Watanabe N, et al. Influence of chronic tethering of the mitral valve on mitral leaflet size and coaptation in functional mitral regurgitation. JACC Cardiovasc Imaging. 2012;5(4):337–45.CrossRef Saito K, Okura H, Watanabe N, et al. Influence of chronic tethering of the mitral valve on mitral leaflet size and coaptation in functional mitral regurgitation. JACC Cardiovasc Imaging. 2012;5(4):337–45.CrossRef
11.
Zurück zum Zitat Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709–17.CrossRef Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709–17.CrossRef
12.
Zurück zum Zitat Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312–8.CrossRef Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312–8.CrossRef
13.
Zurück zum Zitat Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.CrossRef Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.CrossRef
14.
Zurück zum Zitat Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260–9.CrossRef Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260–9.CrossRef
15.
Zurück zum Zitat Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.CrossRef Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.CrossRef
16.
Zurück zum Zitat Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.CrossRef Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.CrossRef
17.
Zurück zum Zitat Watanabe N, Ogasawara Y, Yamaura Y, et al. Quantitation of mitral valve tenting in ischemic mitral regurgitation by transthoracic real-time three-dimensional echocardiography. J Am Coll Cardiol. 2005;45(5):763–9.CrossRef Watanabe N, Ogasawara Y, Yamaura Y, et al. Quantitation of mitral valve tenting in ischemic mitral regurgitation by transthoracic real-time three-dimensional echocardiography. J Am Coll Cardiol. 2005;45(5):763–9.CrossRef
18.
Zurück zum Zitat Yamada R, Watanabe N, Kume T, et al. Quantitative measurement of mitral valve coaptation in functional mitral regurgitation: in vivo experimental study by real-time three-dimensional echocardiography. J Cardiol. 2009;53(1):94–101.CrossRef Yamada R, Watanabe N, Kume T, et al. Quantitative measurement of mitral valve coaptation in functional mitral regurgitation: in vivo experimental study by real-time three-dimensional echocardiography. J Cardiol. 2009;53(1):94–101.CrossRef
19.
Zurück zum Zitat Saito K, Okura H, Watanabe N, et al. Quantification of mitral valve apparatus by three-dimensional transesophageal echocardiography: in vitro validation study comparing two different analysis systems. J Echocardiogr. 2011;9(4):130–6.CrossRef Saito K, Okura H, Watanabe N, et al. Quantification of mitral valve apparatus by three-dimensional transesophageal echocardiography: in vitro validation study comparing two different analysis systems. J Echocardiogr. 2011;9(4):130–6.CrossRef
20.
Zurück zum Zitat Ito K, Abe Y, Takahashi Y, et al. Mechanism of atrial functional mitral regurgitation in patients with atrial fibrillation: a study using three-dimensional transesophageal echocardiography. J Cardiol. 2017;70(6):584–90.CrossRef Ito K, Abe Y, Takahashi Y, et al. Mechanism of atrial functional mitral regurgitation in patients with atrial fibrillation: a study using three-dimensional transesophageal echocardiography. J Cardiol. 2017;70(6):584–90.CrossRef
21.
Zurück zum Zitat Abe Y, Akamatsu K, Ito K, et al. Prevalence and prognostic significance of functional mitral and tricuspid regurgitation despite preserved left ventricular ejection fraction in atrial fibrillation patients. Circ J. 2018;82(5):1451–8.CrossRef Abe Y, Akamatsu K, Ito K, et al. Prevalence and prognostic significance of functional mitral and tricuspid regurgitation despite preserved left ventricular ejection fraction in atrial fibrillation patients. Circ J. 2018;82(5):1451–8.CrossRef
22.
Zurück zum Zitat Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation. 2001;103(13):1759–64.CrossRef Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation. 2001;103(13):1759–64.CrossRef
23.
Zurück zum Zitat Harris KM, Sundt TM 3rd, Aeppli D, et al. Can late survival of patients with moderate ischemic mitral regurgitation be impacted by intervention on the valve? Ann Thorac Surg. 2002;74(5):1468–75.CrossRef Harris KM, Sundt TM 3rd, Aeppli D, et al. Can late survival of patients with moderate ischemic mitral regurgitation be impacted by intervention on the valve? Ann Thorac Surg. 2002;74(5):1468–75.CrossRef
24.
Zurück zum Zitat Kim K, Kaji S, Kasamoto M, et al. Renin–angiotensin system inhibitors in patients with or without ischaemic mitral regurgitation after acute myocardial infarction. Open Heart. 2017;4(2):e000637.CrossRef Kim K, Kaji S, Kasamoto M, et al. Renin–angiotensin system inhibitors in patients with or without ischaemic mitral regurgitation after acute myocardial infarction. Open Heart. 2017;4(2):e000637.CrossRef
25.
Zurück zum Zitat Baldus S, Schillinger W, Franzen O, et al. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2012;14(9):1050–5.CrossRef Baldus S, Schillinger W, Franzen O, et al. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2012;14(9):1050–5.CrossRef
Metadaten
Titel
Predictors and prognostic impact of secondary mitral regurgitation in myocardial infarction with preserved ejection fraction
verfasst von
Maki Nogi
Hiroyuki Okura
Toru Kataoka
Kiyoshi Yoshida
Publikationsdatum
06.11.2019
Verlag
Springer Singapore
Erschienen in
Journal of Echocardiography / Ausgabe 1/2020
Print ISSN: 1349-0222
Elektronische ISSN: 1880-344X
DOI
https://doi.org/10.1007/s12574-019-00451-y

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Kardiologie

Koronare Herzkrankheit: Das waren die Top-Studien 2024

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Kaffeegenuss sicher bei Vorhofflimmern

Menschen mit Vorhofflimmern fürchten oft, Kaffee könnte schlecht für ihr Herz sein. Solche Ängste sind offenbar unbegründet: Zwei Schweizer Untersuchungen deuten sogar auf eine reduzierte Rate von kardiovaskulären Ereignissen unter Kaffeetrinkern.

Mit jedem Defibrillationsversuch sinkt die Überlebenschance

Wie wirkt es sich auf die Prognose aus, wenn bei Herzstillstand einmal, zweimal oder gar 29 Mal geschockt werden muss? Laut einer aktuellen Studie besteht ein deutlicher Zusammenhang zwischen der Zahl der Defibrillationsversuche und den Überlebenschancen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.